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Spinal muscular atrophy (SMA), a common neuromuscular disorder, is caused by homozygous absence of the
survival motor neuron gene 1 (SMN1), while the disease severity is mainly inﬂuenced by the number of SMN2
gene copies. This correlation is not absolute, suggesting the existence of yet unknown factors modulating
disease progression. We demonstrate that the SMN2 gene is subject to gene silencing by DNA methylation.
SMN2 contains four CpG islands which present highly conserved methylation patterns and little interindividual
variations in SMN1-deleted SMA patients. The comprehensive analysis of SMN2 methylation in patients
suffering from severe versus mild SMA carrying identical SMN2 copy numbers revealed a correlation of CpG
methylation at the positions 2290 and 2296 with the disease severity and the activity of the ﬁrst transcriptional
start site of SMN2 at position 2296. These results provide ﬁrst evidence that SMN2 alleles are functionally not
equivalent due to differences in DNA methylation. We demonstrate that the methyl-CpG-binding protein 2, a
transcriptional repressor, binds to the critical SMN2 promoter region in a methylation-dependent manner.
However, inhibition of SMN2 gene silencing conferred by DNA methylation might represent a promising
strategy for pharmacologic SMA therapy. We identiﬁed histone deacetylase (HDAC) inhibitors including vorino-
stat and romidepsin which are able to bypass SMN2 gene silencing by DNA methylation, while others such as
valproic acid and phenylbutyrate do not, due to HDAC isoenzyme speciﬁcities. These ﬁndings indicate that
DNA methylation is functionally important regarding SMA disease progression and pharmacological SMN2
gene activation which might have implications for future SMA therapy regimens.
INTRODUCTION
Autosomal recessive proximal spinal muscular atrophy (SMA)
is a severely progressing neuromuscular disorder and a major
cause of inherited childhood lethality. SMA is characterized
by the loss of lower motor neurons in the anterior horns of
the spinal cord, causing symmetrical weakness and atrophy
of voluntary muscles. Patients with SMA have been classiﬁed
into four types depending on age of onset and progression of
the disease: type I SMA is the most severe form with general-
ized muscle weakness and hypotonia and a disease onset
within the ﬁrst 6 months of life. The children are unable to
sit or walk and usually die within the ﬁrst 2 years of life.
Type II SMA individuals are able to sit but unable to walk
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months of life and survive beyond 2 years. Type III SMA
patients are able to sit and walk, and the lifespan is not
reduced. Disease onset before the age of 3 years is classiﬁed
as type IIIa, whereas an age of onset beyond 3 years is classi-
ﬁed as type IIIb SMA. Type IV SMA patients are mildly
affected with an age of onset after the third decade of life
(reviewed in 1).
The disease determining survival motor neuron gene 1
(SMN1) is homozygously absent in 96% of all SMA patients
and intragenic SMN1 mutations are rare (2). Within the
SMA region on chromosome 5q, the human survival motor
neuron (SMN) gene exists in two copies, SMN1 and SMN2,
which are ubiquitously expressed and encode identical pro-
teins (3). Even though all SMA patients lacking SMN1 carry
at least one SMN2 gene copy, the amount of functional
SMN protein produced by SMN2 is not sufﬁcient to prevent
progressive a-motor neuron degeneration. This ﬁnding has
been assigned to a single translationally silent ‘C’ to ‘T’ tran-
sition within exon 7, affecting the splicing of primary SMN
transcripts (4). As a consequence, the disease determining
SMN1 gene produces full-length transcripts only (FL-SMN),
whereas the majority of SMN2 transcripts lack exon 7 due to
alternative splicing (D7-SMN). Truncated D7-SMN proteins
are reduced in their ability to self-oligomerize, which is essen-
tial for proper SMN function (5,6), and have been shown to
ameliorate, but not to prevent, the SMA phenotype in vivo
(7). However, several studies have revealed a strong inverse
correlation between the number of SMN2 copies and SMA
severity (8–11). Most type I SMA patients carry two SMN2
copies, whereas type II SMA patients carry three and type
III SMA patients carry three or four SMN2 copies. Rarely,
patients with two SMN2 copies show mild phenotypes (9),
suggesting the inﬂuence of yet unidentiﬁed modifying
factors modulating disease progression. Due to the disease
modifying property of the SMN2 gene which has been veriﬁed
in transgenic mouse models (12), SMN2 represents the major
therapeutic target. Consequently, transcriptional SMN2 acti-
vation and/or modulation of the SMN2 splicing pattern to
increase FL-SMN levels may be an effective strategy for
SMA treatment.
Numerous small-molecule histone deacetylase (HDAC)
inhibitors have been shown to increase SMN2-derived
FL-SMN protein levels in vitro by transcriptional activation
and/or by modulation of the SMN2 splicing pattern. These
compounds include the fatty acids sodium butyrate (SB),
phenylbutyrate (PB) and valproic acid (VPA) (13–17); the
benzamide M344 (15,18) as well as the hydroxamic acids
SAHA and trichostatin A (TSA) (15,19,20). The potential
applicability of HDAC inhibitors for SMA therapy was con-
ﬁrmed in transgenic mice which mimic SMA-like features.
By employing a knockout transgenic mouse model, Chang
et al. (17) demonstrated that oral application of SB increased
lifespan and SMN2-derived SMN protein levels in motor
neurons of affected mice. Concordantly, Tsai et al. (21)
demonstrated that oral application of VPA attenuates motor
neuron death, increases spinal SMN protein levels and par-
tially normalizes motor function in SMA-like mice. Clinical
phase II trials have been initiated to evaluate the efﬁcacy of
the FDA-approved drugs PB and VPA for SMA therapy.
Pilot trials with small numbers of patients treated with PB
(22,23) or VPA (24,25) revealed elevated FL-SMN2 transcript
levels in some patients and increased quantitative muscle
strength and subjective muscle function, which might further
emphasize the potential use of HDAC inhibitors for SMA
treatment.
However, the efﬁcacies of PB and VPA for SMA therapy
await clinical conﬁrmation and the mechanism(s) by which
HDAC inhibitors elevate transcriptional SMN2 gene activity
remain elusive. In general, HDAC inhibition promotes a
more relaxed chromatin structure, allowing transcriptional
activation. Given the fact that the fundamental mechanisms
of epigenetic gene regulation, histone modiﬁcation and DNA
methylation have shown to be intimately interlinked (26,27),
we hypothesized that DNA methylation plays a pivotal role
in epigenetic SMN2 gene regulation and SMA pathogenesis.
DNA methylation has been shown to be the most stable type
of epigenetic modiﬁcation modulating the transcriptional plas-
ticity of mammalian genomes (28). However, the role of DNA
methylation in SMN2 gene regulation has not been addressed
so far. In this study, we demonstrate for the ﬁrst time that
the SMN2 gene is subject to gene silencing by DNA methyl-
ation, which might have major implications for SMA disease
progression and upcoming pharmacological interventions for
epigenetic SMA therapy.
RESULTS
SMN2 gene activity is reduced by DNA methylation
We raised the question whether the major target gene for SMA
therapy, SMN2, is subject to gene silencing mediated by DNA
methylation. To address this issue, SMN1-deleted ﬁbroblast
cell lines (ML5, ML16) derived from two independent
SMA patients carrying three SMN2 copies were treated with
various doses of 5-aza-20-deoxycytidine (Aza), a well-
established DNA-demethylating compound. Aza treatment
increased SMN2-derived transcript and protein levels in a
dose-dependent fashion in both SMA ﬁbroblast cell lines
(Fig. 1A and B), indicating that SMN2 gene activity is inver-
sely correlated with DNA methylation. Using both cell lines,
we previously have shown that HDAC inhibitors augment
SMN2 protein levels by transcriptional SMN2 gene activation
and increased SMN2 exon 7 inclusion (14,15,18). Concor-
dantly, treatment of SMA ﬁbroblasts (ML16) with effective
doses of the experimental pan-HDAC inhibitor M344 signiﬁ-
cantly increased total SMN2 transcript levels (Fig. 1C).
However, even though interference with either DNA methyl-
ation or HDAC activity was sufﬁcient to increase SMN2
gene expression, there is no additive or synergistic effect
when combined (Fig. 1C).
SMN2 is a methylated gene containing four CpG islands
To identify putative CpG islands (CGIs) involved in epige-
netic SMN2 gene regulation by DNA methylation, we ana-
lysed the genomic region 3000 nucleotides (nt) upstream and
downstream of the translational SMN2 start site (deﬁned as
nt position þ1). By employing the CGI ﬁnder algorithm
(www.EBI.ac.uk/emboss) we identiﬁed four putative CGIs
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þ1146) surrounding the translational SMN2 start site
(Fig. 2A). These four putative CGIs, subsequently referred
to as
SMN2CGIs, contain a total of 85 CpG dinucleotides, 14
of which are located in
SMN2CGI 1 (nt 2896 to 2645), 12
in
SMN2CGI 2 (nt 2469 to 2247), 38 in
SMN2CGI 3 (nt
2151 to þ295) and 21 in
SMN2CGI 4 (nt þ844 to þ1146).
To quantify DNA methylation levels of each CpG dinucleotide
located within the four
SMN2CGIs, we performed bisulphite
genomic sequencing using pyrosequencing technology (29).
The method is based on the selective deamination of unmethy-
lated cytosine to uracil by treatment with bisulphite, while
5-methylcytosine remains unchanged. Pyrosequencing of sub-
sequently generated PCR (polymerase chain reaction) pro-
ducts allows for both the detection and the quantiﬁcation of
cytosine methylation. Using genomic DNA isolated from
SMN1-deleted SMA ﬁbroblasts (ML5, ML16), bisulphite
genomic sequencing revealed almost identical SMN2 methyl-
ation patterns in both SMA ﬁbroblast cell lines (Fig. 2B).
SMN2CGI 1 and
SMN2CGI 4 were hypermethylated in both
cell lines with mean methylation levels .70%.
SMN2CGI 3
was hypomethylated (mean methylation levels ,10%) with
a single outlier at nt position þ89, while
SMN2CGI 2 displayed
intermediate mean methylation levels. Using bisulphite-
treated DNA derived from ML5 and ML16 SMA ﬁbroblasts
as templates, cloning and sequencing of PCR products
revealed similar results. Again,
SMN2CGI 1 and
SMN2CGI 4
were almost completely methylated,
SMN2CGI 3 was nearly
unmethylated (data not shown), while
SMN2CGI 2 showed
intermediate methylation levels (Fig. 2C).
SMN2 gene methylation patterns are highly conserved and
correlate with SMA severity
The vast majority of SMN1-deleted SMA patients carrying
two SMN2 copies suffer from type I or II SMA, while only
few patients (2%) develop a mild (type III SMA) pheno-
type (9), suggesting the existence of a yet unknown factor
counteracting disease progression. To address whether
SMN2 gene methylation correlates with the disease severity,
we analysed methylation levels of each CpG dinucleotide
within the
SMN2CGIs using DNA isolated from blood
samples taken from 10 unrelated, SMN1-deleted type I
SMA patients carrying two SMN2 copies (six females, four
males). Bisulphite genomic sequencing identiﬁed SMN2
methylation patterns similar to those observed in SMA ﬁbro-
blasts (Fig. 3A), suggesting that SMN2 gene methylation
patterns do not essentially differ between tissues. Again,
SMN2CGI 1 and
SMN2CGI 4 appeared to be hypermethylated,
SMN2CGI 3 hypomethylated with a single outlier at position
þ89, while
SMN2CGI 2 displayed intermediate mean methyl-
ation levels. An unexpected observation was that methylation
levels of each single CpG dinucleotide showed only little
Figure 1. Transcriptional survival motor neuron gene 2 (SMN2) activation by
the DNA-demethylating drug 5-aza-20-deoxycytidine (Aza) in SMN1-deleted
SMA (spinal muscular atrophy) ﬁbroblasts. Bar graphs show SMN2 transcript
(A) and SMN2 protein levels (B) in ML5 and ML16 ﬁbroblast cell lines
treated with various doses of Aza for 72 h (mean+SEM). Expression
levels in solvent- and time-matched controls were set to 100%. Increased
SMN2 transcript levels (normalized to ß-actin) were observed following Aza
treatment (1, 10, 100 mM) and a dose-dependent SMN2 gene activation was
conﬁrmed on protein level (normalized to ß-tubulin). A representative
western blot analysis (ML16) is shown. (C) Quantiﬁcation of SMN2 transcript
levels (normalized to ß-actin) in ML16 cells after treatment with different
doses of the SMN2-activating HDAC (histone deacetylase) inhibitor M344
either alone or in combination with 10 mM Aza for 48 h. Transcriptional
SMN2 gene activation either by M344 alone or in combination with Aza
(10 mM) reached levels of signiﬁcance in all cases (P , 0.05, t-test). A
.5-fold induction was observed following treatment with 10 mM M344
(546+53%), while no additive effects were observed after co-treatment
with 10 mM Aza (P . 0.05, t-test).
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(Fig. 3A). The subsequent analysis of DNA isolated from
blood samples taken from seven available SMN1-deleted
type III SMA patients carrying two SMN2 copies (four
females, three males) again revealed little interindividual
variations (Fig. 3B). However, the comparison of methylation
levels of each CpG dinucleotide identiﬁed signiﬁcant corre-
lations between CpG methylation levels and the disease
severity at seven CpGs located in
SMN2CGI 1 (nt 2871,
2695),
SMN2CGI 2 (nt 2296, 2290), and
SMN2CGI 4 (nt
þ855, þ988, þ1103) (Fig. 3C). At six sites (nt 2871,
2695, 2296, 2290, þ855, þ1103), signiﬁcantly lower
methylation frequencies were observed in type III compared
with type I SMA patients. A striking ﬁnding at this point
was that the most pronounced differences in CpG methylation
levels were observed at nt position 2296 (
SMN2CGI 2; type I
SMA: 94.1+6.3%; type III SMA: 66.7+8.0%, P ¼
0.000084, t-test), which exactly represents the ﬁrst out of
three transcriptional start sites (TSS) of SMN2 (Fig. 2A)
(30,31). The correlation of CpG methylation levels of all
17 patients with their gender (10 females, seven males) did
not reveal any signiﬁcant results (data not shown), which is
in line with a previous comprehensive study showing that
DNA methylation is not affected by gender (28).
Figure 2. Survival motor neuron gene 2 (SMN2) is a methylated gene containing four CpG islands (CGIs). Putative CGIs within the genomic region 3000 nucleo-
tides (nt) upstream and downstream the translational SMN2 start site (NCBI36: 5:70254287:70248287) were identiﬁed using the CGI ﬁnder and plotting tool
(www.EBI.ac.uk/emboss). This algorithm identiﬁed four putative CGIs within the respective genomic region (
SMN2CGI 1: nt 2896 to 2645,
SMN2CGI 2: nt
2469 to 2247,
SMN2CGI 3: nt 2151 to þ295,
SMN2CGI 4: nt þ844 to þ1146).
SMN2CGI 2 contains the ﬁrst out of three transcriptional start sites (TSS) of
SMN2 at nt 2296, while the second TSS at nt position 2242 is located close to the downstream border of
SMN2CGI 2 (30,31). (A) Schematically illustrates
the localizations of all four
SMN2CGIs within the analysed genomic region. The localizations of the TSS at nt positions 2296, 2242 and 2163 are indicated
(30,31). (B) Frequency plots illustrating the methylation levels of each CpG dinucleotide within each
SMN2CGI in the respective SMA(Spinal muscular atrophy)-
ﬁbroblasts. The mean methylation levels of each
SMN2CGI, indicated by a horizontal line, are as follows: ML5:
SMN2CGI 1: 87.1%,
SMN2CGI 2: 36.6%,
SMN2CGI
3: 6.9%,
SMN2CGI 4: 75.9%; ML16:
SMN2CGI 1: 87.7%,
SMN2CGI 2: 37.7%,
SMN2CGI 3: 6.2%,
SMN2CGI 4: 73.4%. (C) Methylation analysis of
SMN2CGI 1,
SMN2CGI 2 and
SMN2CGI 4 in ML5 and ML16 ﬁbroblasts cell lines by bisulphite treatment, followed by PCR ampliﬁcation of the respective
SMN2CGI,
cloning of PCR products, and sequencing. The methylation patterns of nine independent clones for each
SMN2CGI and each cell line are shown. Empty
circles represent unmethylated CpGs, whereas full circles correspond to their methylated status.
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patients. Bar charts show the mean methylation levels (+SEM) of each CpG dinucleotide within the respective
SMN2CGIs in DNA isolated from blood
samples drawn from SMN1-deleted SMA patients carrying two SMN2 copies (A, B). Type I (n ¼ 10) and type III SMA patients (n ¼ 7) show highly conserved
SMN2 methylation patterns as can be deduced from the comparatively low SEM for the methylation levels of each CpG dinucleotide. The mean methylation
levels of each
SMN2CGI (see frequency plot) in both groups are as follows: type I SMA –
SMN2CGI 1: 89.1%,
SMN2CGI 2: 58.0%,
SMN2CGI 3: 4.6%,
SMN2CGI 4: 79.9%; type III SMA –
SMN2CGI 1: 85.5%,
SMN2CGI 2: 52.6%,
SMN2CGI 3: 4.8%,
SMN2CGI 4: 78.1%. SMN2 methylation correlates with the
disease severity. Bar chart shows differences in DNA methylation at each CpG dinucleotide in type I versus type III SMA patients (C). Seven CpG dinucleotides
(nt 2871, 2695, 2296, 2290, þ855, þ988, þ1103) were identiﬁed whose methylation frequencies differ by at least 10% in type I versus type III SMA
patients. Correlations between CpG methylation frequencies and disease severity reached levels of signiﬁcance in all seven cases. Three levels of statistical
signiﬁcance were discriminated:  P , 0.05,   P , 0.01,    P , 0.001 (t-test).
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of the SMN2 gene is associated with mild SMA in
SMA ﬁbroblasts
To validate a correlation between SMN2 gene methylation and
the disease severity we analysed ﬁbroblasts cell lines derived
from independent SMN1-deleted SMA patients, also carrying
two SMN2 copies. Repeated quantiﬁcation of CpG methylation
levels at nt positions 2296 and 2290 (both
SMN2CGI 2) corro-
borated a signiﬁcant correlation between CpG methylation and
diseaseseverityintypeI(ML17),typeIIIa(ML22)andtypeIIIb
SMA ﬁbroblasts (ML74) (Fig. 4A). No signiﬁcant differences
were observed at the remaining ﬁve positions (2871, 2695,
þ855, þ988, þ1103, data not shown) demonstrated to be dif-
ferentially methylated in DNA isolated from blood (Fig. 3C).
Given the fact that the nearby CpG dinucleotides at nt positions
2296 and 2290 co-localize withthe ﬁrst TSSofSMN2located
atntposition 2296,itappearsevidentthatmethylationlevelsat
thesesitesmodulate theexpressionofSMN2transcriptsderived
from this TSS (subsequently designated as the long transcript
SMN2, LT-SMN2). Using different primer combinations which
speciﬁcally amplify LT-SMN2, an inverse correlation between
2296 and 2290 methylation levels and LT-SMN2 transcript
levelswasobserved intypeI,typeIIIaand typeIIIb SMAﬁbro-
blast cell lines (Fig. 4B and C). However, no signiﬁcant differ-
ences in total SMN2 protein levels were detected in ML17,
ML22 and ML74 ﬁbroblasts due to the ﬁnding that LT-SMN2
transcripts account for ,5% of total SMN2 transcripts in these
cells (data not shown).
HDAC inhibitor treatment bypasses LT-SMN2 gene
silencing mediated by DNA methylation
Based on the observation that DNA methylation restricts SMN2
geneactivity(Fig.1AandB),wehypothesizedthattheabolition
of SMN2 gene silencing conferred by DNA methylation might
represent a promising strategy for pharmacologic SMA
therapy. In 1998, Jones et al. (26) have shown that the exper-
imental pan-HDAC inhibitor TSA is able to bypass gene silen-
cingmediatedbyDNAmethylation.Toaddressthisissue,typeI
SMA ﬁbroblasts (ML17) showing high methylation levels at
positions 2296 and 2290 associated with low LT-SMN2
mRNA expression (Fig. 4) were treated with effective doses
of highly potent HDAC inhibitors of different chemical
classes.Speciﬁcally,cellswereexposedtoSAHA,M344,scrip-
taid, oxamﬂatin (hydroxamic acids), or romidepsin (FK-228,
cyclic tetrapeptide) for 48 h. All ﬁve test compounds dramati-
cally increased LT-SMN2 transcript levels dose dependently,
indicating that HDAC inhibitors are able to relieve LT-SMN2
gene silencing mediated by DNA methylation (Fig. 5A and
B). In all analyses, the dose-dependent inductions of
LT-SMN2 expression were associated with robustly increased
total SMN2 transcript levels. For example, treatment with
30 mM doses of SAHA results in a 25-fold induction of
LT-SMN2 and a 5-fold induction of total SMN2 transcript
levels (Fig. 5B). However, the hitherto analysed HDAC inhibi-
tors possess negligible HDAC isoenzyme selectivities and con-
cordantly we previously have shown that these compounds are
able to fully antagonize HDAC activity in vitro (32). Thus, we
next assessed whether isoenzyme selective HDAC inhibitors
such as MS-275 as well as VPA and PB, which are both under
clinicalevaluationforSMAtherapy,showsimilareffects.Inter-
estingly,neitherthebenzamideMS-275northefattyacidsVPA
and PB were able to substantially elevate LT-SMN2 transcript
levels even at excessive doses (Fig. 5B), indicating that
MS-275, VPA and PB were not able to overcome LT-SMN2
gene silencing conferred by DNA methylation in this exper-
imental setting. To conﬁrm these ﬁndings in a neuroectodermal
tissue we subsequently employed human hippocampal brain
Figure 4. Low survival motor neuron gene 2 (SMN2) methylation levels at the positions 2296 and 2290 are associated with mild spinal muscular atrophy
(SMA) in SMA ﬁbroblasts. (A) Bar chart showing the mean methylation levels (+SEM) at positions 2296 and 2290 in ﬁbroblasts derived from SMN1-deleted
SMA patients carrying two SMN2 copies. At both sites, type I SMA ﬁbroblasts (ML17) show signiﬁcantly higher methylation levels than ﬁbroblasts derived from
type IIIa (ML22) and type IIIb (ML74) patients. Three levels of statistical signiﬁcance were discriminated:  P , 0.05,   P , 0.01,    P , 0.001 (t-test). Methyl-
ation levels at positions 2296 and 2290 correlate with the activity of the transcriptional start site (TSS) at position 2296 in SMA ﬁbroblasts. Relative to type I
SMA ﬁbroblasts (ML17), the low methylation levels at positions 2296 and 2290 observed in type IIIa and type IIIb SMA ﬁbroblasts are associated with high
SMN2 transcripts levels originated from the TSS at position 2296 (LT-SMN2) as shown by semi-quantitative RT–PCR analyses using two different primer
combinations. (B) ß-Actin primers were used as internal control to verify equal loading of cDNA. CDK4 primers were used to detect potential contaminations
with genomic DNA (amplicon size cDNA: 262 bp, amplicon size gDNA: 420 bp). (C) Differences in LT-SMN2 expression levels were conﬁrmed by real-time
PCR (normalized to ß-actin) using the LT-SMN2
2279,2128 primer pair. Data are given as mean percentage (+SEM) relative to LT-SMN2 transcript levels in type
I SMA ﬁbroblasts (ML17) which were set to 100%.
Human Molecular Genetics, 2009, Vol. 18, No. 2 309slicecultures(OHSCs)derivedfromepilepsysurgery(fourindi-
viduals, Fig. 6A–D). Even though LT-SMN transcripts derived
from the SMN1 or SMN2 genes were not distinguishable in
thisexperimentalparadigmduetoidenticalpromotersequences
(33), a pronounced induction of LT-SMN transcription was
observed following treatment with M344 (Fig. 6A) or SAHA
(Fig. 6B and C), while VPA again had no or only moderate
effects (Fig. 6B–D). A dose-dependent induction of SMN
expression following treatment with M344 was conﬁrmed on
protein level (Fig. 6A).
Transcriptional LT-SMN2 induction by HDAC
inhibitors is not mediated by DNA-demethylation
of the SMN2 gene
The mechanism by which pan-HDAC inhibitors such as
SAHA and romidepsin (FK-228) bypass LT-SMN2 silencing
by DNA methylation remains elusive. In single cell cultures,
TSA and VPA have shown to trigger DNA demethylation in
a replication-independent manner (34–36) and gene-speciﬁc
DNA demethylating activities of VPA, MS-275 and TSA
have subsequently been conﬁrmed in vivo (37,38). To assess
whether HDAC inhibitors elevate LT-SMN2 transcript levels
due to their propensity to promote DNA demethylation, we
next analysed the methylation levels of
SMN2CGI 2 in type I
SMA ﬁbroblasts (ML17) following HDAC inhibitor treatment
for 48 h. Using 10 mM doses of SAHA, this experimental
setting has shown to substantially elevate LT-SMN2 and total
SMN2 transcript levels (Fig. 5A and B). However, SAHA
did not promote
SMN2CGI 2 demethylation and neither did
VPA or PB as shown by bisulphite genomic sequencing
(Fig. 7A). In contrast, treatment of ML17 cells with zebular-
ine, a DNA-demethylating drug structurally related to Aza,
induced
SMN2CGI 2 demethylation (Fig. 7A and B), and con-
sistent with previous ﬁndings, reduced
SMN2CGI 2 methylation
levels including the nt positions 2296 and 2290 associated
with signiﬁcantly increased LT-SMN2 transcript levels
(Fig. 7B and C). These results suggest that transcriptional
LT-SMN2 induction by HDAC inhibitors is not mediated by
DNA-demethylation of the SMN2 gene promoter.
Figure 5. Histone deacetylase (HDAC) inhibitor treatment bypasses LT-SMN2 gene silencing mediated by DNA methylation. Treatment of type I SMA (spinal
muscular atrophy) ﬁbroblasts (ML17) with increasing doses of SAHA (hydroxamic acid) or FK-228 (cyclic tetrapeptide) elevates LT-SMN2 transcript levels in a
dose-dependent manner as shown by semi-quantitative RT–PCR analyses. (A) ß-Actin primers were used as internal control to verify equal loading of cDNA.
LT-SMN2 and total SMN2 transcript levels in type I SMA ﬁbroblasts (ML17) following treatment with HDAC inhibitors for 48 h were further analysed by real-
time PCR. (B) LT-SMN2 and total SMN2 transcript levels (both normalized to ß-actin) following HDAC inhibitor treatment are given as mean percentages
(+SEM) relative to LT-SMN2 and total SMN2 transcript levels in solvent- and time-matched controls which were set to 100%.
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promoter and mediates transcriptional
LT-SMN2 silencing
Two basic models evolved regarding the mechanism by which
DNA methylation affects transcription (39). DNA methylation
can directly repress transcription by blocking transcriptional
activators from binding to cognate DNA sequences, alterna-
tively methyl-CpG DNA-binding proteins (MBPs) recognize
methylated DNA and recruit co-repressors to silence gene
expression directly. Since HDAC inhibitors do not promote
SMN2 gene demethylation in our experimental setting
(Fig. 7A), and are able to bypass LT-SMN2 gene silencing
by DNA methylation (Figs 5 and 6), we hypothesized that
DNA methylation at the SMN2 promoter region is recognized
by an MBP which recruits HDAC activity to mediate epige-
netic gene silencing. Previous studies revealed that two
global mechanisms of epigenetic gene regulation, DNA
methylation and histone deacetylation, can be linked by the
methyl-CpG-binding-protein 2 (MeCP2) (27). MeCP2 is an
abundant chromosomal protein that speciﬁcally binds to
methylated DNA and requires HDAC activity to repress
transcription from methylated promoters (26,27). Thus, we
hypothesized that the methylated SMN2 promoter is recog-
nized by MeCP2. In line with this hypothesis, siRNA-
mediated knockdown of MeCP2 resulted in signiﬁcantly
increased LT-SMN2 transcript levels in ML17 type I SMA
ﬁbroblast cells (Fig. 7D). To validate the role of MeCP2 in
LT-SMN2 expression, we next analysed the potential binding
of MeCP2 to the SMN2 promoter region by chromatin immu-
noprecipitation (ChIP). Initial analyses using
SMN2CGI 2-
speciﬁc primers covering the genomic region from nt 2372
to 2266 revealed a clear association of MeCP2 with the
SMN2 promoter region in ML17 SMA ﬁbroblasts (Fig. 7E).
Elevated LT-SMN2 transcript levels following treatment of
ML17 ﬁbroblasts with zebularine (Fig. 7C) are associated
with a decrease in the MeCP2 binding to the SMN2 promoter
(Fig. 7F), indicating that MeCP2 recognizes the SMN2 promo-
ter in a methylation-dependent fashion. Moreover, increased
LT-SMN2 transcript levels following siRNA-mediated knock-
down of MeCP2 (Fig. 7D) are associated with decreased
MeCP2 binding to the SMN2 promoter (77.8+4.6%, P ,
0.05, t-test). These data indicate a methylation-dependent
binding of the transcriptional repressor MeCP2 to the SMN2
promoter region resulting in LT-SMN2 silencing. To determine
the binding pattern of MeCP2 on the SMN2 promoter we
performed MeCP2 ChIP analyses using ML17 SMA ﬁbro-
blasts and six different primer pairs covering the genomic
SMN2 promoter region from nt 2631 to þ59, which com-
prises
SMN2CGI 2 (nt 2469 to 2247) and adjacent sequences.
Although MeCP2 binding was detectable in all cases
(Fig. 7G), ChIP-PCR signal intensities were substantially
higher at the genomic region from nt 2349 and 263,
suggesting enrichment at this site. This particular 286 bp
region contains all three transcriptional SMN2 start sites
at positions 2296, 2242 and 2163 and the differen-
tially methylated CpG dinucleotides at positions 2296 and
2290, suggesting a probable role of MeCP2 in SMN2 gene
silencing.
DISCUSSION
Here, we show for the ﬁrst time that SMN2, the major disease
modiﬁer and target gene for pharmacological SMA treatment,
is epigenetically regulated by DNA methylation given by the
Figure 6. HDAC (histone deacetylase) inhibitor treatment elevates LT-SMN
expression in human organotypic hippocampal brain slice cultures (OHSCs).
(A–D) Bar charts showing LT-SMN and total survival motor neuron (SMN)
transcript levels in human OHSCs derived from four different individuals.
OHSCs were treated with the indicated doses of M344, SAHA or VPA (val-
proic acid) for 48 h. LT-SMN and total SMN transcript levels (both normalized
to ß-actin) are given as mean percentages (+SEM) relative to LT-SMN and
total SMN transcript levels in solvent- and time-matched controls which
were set to 100%. Using OHSCs derived from the ﬁrst patient (A), a dose-
dependent SMN induction was conﬁrmed on protein level (relative to
ß-tubulin; 8 mM: 138+2%; 16 mM: 188+30%; 32 mM: 219+41%). A repre-
sentative human OHSC and a representative western blot analysis are shown.
Induction of SMN protein expression by M344 reached levels of signiﬁcance
at all indicated doses (P , 0.05, t-test).
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activity (Figs 1A and B, and 7C). We demonstrate that SMN2
contains four putative CGIs (
SMN2CGIs) located within the
genomic region 896 nt upstream and 1146 nt downstream of
its translational start site (Fig. 2A). Analysis of DNA isolated
from ﬁbroblast cell lines and blood samples derived from
SMN1-deleted SMA patients identiﬁed
SMN2CGI 1 and
SMN2CGI 4 to be hypermethylated,
SMN2CGI 3 appeared to
be almost methylation-free, while
SMN2CGI 2 showed inter-
mediate methylation levels (Figs 2B and C, and 3A–C).
Since CGIs are usually deﬁned as short unmethylated DNA
patches (29), solely
SMN2CGI 3 (446 bp, GC content 62.1%)
Figure 7. LT-SMN2 induction by HDAC (histone deacetylase) inhibitors is not mediated by survival motor neuron gene 2 (SMN2) promoter demethylation. (A)
Treatment of type I spinal muscular atrophy (SMA) ﬁbroblasts (ML17) with valproic acid (VPA) (10 mM), phenylbutyrate (PB) (1 mM) or SAHA (10 mM) for
48 h did not affect
SMN2CGI 2 methylation levels. Frequency plot illustrating methylation levels of each CpG dinucleotide within the
SMN2CGI 2 in treated ML17
cells compared with time- and solvent-matched ML17 control ﬁbroblasts. The DNA-demethylating drug zebularine (ZEB, 100 mM) was used as positive control.
The mean methylation levels of
SMN2CGI 2, indicated by horizontal lines, are as follows – control: 47.0%, VPA: 44.5%, PB 44.1%, SAHA: 45.0%, ZEB: 37.3%.
Demethylation of CpG dinucleotides at positions 2296 and 2290 is associated with increased LT-SMN2 expression. Treatment of type I SMA ﬁbroblasts
(ML17) with ZEB (100 mM, 48 h) results in a signiﬁcant demethylation of nine out of 12 CpG dinucleotides located in
SMN2CGI 2, including the nt positions
2296 and 2290. (B) ZEB-induced
SMN2CGI 2 demethylation is associated with increased LT-SMN2 levels as shown by quantitative real-time PCR. LT-SMN2
transcript levels (normalized to ß-actin) are given as mean percentages (+SEM) relative to LT-SMN2 expression levels in solvent- and time-matched controls set
to 100%. (C) siRNA-mediated knockdown of MeCP2 elevates LT-SMN2 transcript levels in ML17 SMA ﬁbroblasts. (D) MeCP2 and LT-SMN2 transcript levels
(normalized to ß-actin) are given as mean percentages (+SEM) relative to MeCP2 or LT-SMN2 expression levels in time-matched controls transfected with
AllStars negative control siRNA. The transcriptional co-repressor methyl-CpG-binding-protein 2 (MeCP2) is associated with the SMN2 promoter region and
binds in a methylation-dependent fashion. (E, F) Using SMN1-deleted SMA ﬁbroblasts cells (ML17), a signiﬁcant binding of MeCP2 to the SMN2 promoter
region was observed by chromatin immunoprecipitation (ChIP) analysis using an anti-MeCP2 antibody and primers amplifying the genomic SMN2 promoter
region from nt 2372 to 2266. An unrelated antibody (negative Ctrl IgG, rabbit, Diagenode) was used as negative control. Treatment of ML17 SMA ﬁbroblast
cells with 100 mM ZEB resulted in a signiﬁcant reduction of MeCP2 binding to the SMN2 promoter region. MeCP2 is enriched at a 286 bp SMN2 promoter
region. (G) ChIP analyses using ML17 ﬁbroblasts and six different primer pairs covering the genomic SMN2 promoter region from nt 2631 to þ59. Enrichment
after MeCP2 ChIP was detectable for all primer pairs while two primer pairs showed considerably higher ChIP-PCR signal intensities. Three levels of statistical
signiﬁcance were discriminated:  P , 0.05,   P , 0.01,    P , 0.001 (t-test).
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egorize
SMN2CGI 1 (252 bp, GC content 54.8%),
SMN2CGI 2
(223 bp, GC content 58.3%) and
SMN2CGI 4 (303 bp, GC
content 59.4%) as ‘weak’ CGIs due to their small size and
comparatively low GC content (40). Differences between the
‘classical’
SMN2CGI 3 and the ‘weak’
SMN2CGIs 1, 2 and 4
become more apparent when calculating the CpG density,
which is deﬁned as the ratio between observed versus expected
CpG dinucleotides (40). Although
SMN2CGI 3 possesses a high
CpG density (0.94) usually found in unmethylated CGIs, the
remaining
SMN2CGIs show intermediate CpG densities
(
SMN2CGI 1: 0.74,
SMN2CGI 2: 0.79,
SMN2CGI 4: 0.79) charac-
teristic for weak CGIs (29). In line with our data (Figs 2B and
C, and 3A and B), weak CGIs usually show high frequencies
of DNA methylation (40). Moreover, SMN2 appears to be a
typical gene regarding its CGI distribution. Approximately
70% of human genes are linked to promoter CGIs (41) and
about half of all CGIs were found at the TSS of an annotated
gene (such as
SMN2CGI 2) (29). Among the four
SMN2CGIs
analysed, we provide ﬁrst evidence that particularly the
genomic region comprising the weak
SMN2CGI 2 is function-
ally important regarding SMA disease progression and
pharmacological SMA therapy.
Even though SMN2 has been identiﬁed as the major SMA
disease modiﬁer, differences in disease progression have fre-
quently been observed in the presence of identical SMN1
mutations and SMN2 copy numbers (9,42). In the presence
of two SMN2 copies, homozygous absence of SMN1 causes
type I SMA in approximately two-thirds of all patients,
while milder phenotypes are consequently also quite
common (9,42). These ﬁndings led to the hypothesis that
SMN2 genes are not functionally equivalent. Using DNA
derived from comparatively easily accessible sources such
as blood and skin we identiﬁed signiﬁcantly lower methyl-
ation levels at two adjacent CpG dinucleotides in type III
SMA patients compared with patients suffering from severe
type I SMA (nt positions 2296 and 2290, both
SMN2CGI
2, Figs 3C and 4A), suggesting that the capability of the
SMN2 gene copies to counteract SMA disease progression
is modulated by DNA methylation. The functional relevance
of DNA methylation at nt positions 2296 and 2290 is
further highlighted by the ﬁnding that these CpG dinucleo-
tides co-localize with the ﬁrst TSS of SMN2 at nt position
2296 (Fig. 2A). We demonstrate that methylation levels at
nt positions 2296 and 2290 inversely correlate with the
activity of the ﬁrst TSS of SMN2 (Figs 4A–C, and 7B and
C) indicating that DNA methylation at these nt positions is
linked with transcriptional LT-SMN2 silencing. In summary,
our data provide ﬁrst evidence that SMN2 gene copies are
not functionally equivalent due to differences in DNA
methylation affecting LT-SMN2 expression. However,
LT-SMN2 contributes only moderately to total SMN2 tran-
script levels in SMA ﬁbroblasts (described earlier). To
address the question whether LT-SMN2 expression is regu-
lated in a tissue-dependent fashion, we subsequently quanti-
ﬁed LT-SMN2 and total SMN2 transcript levels in various
tissues derived from adult transgenic mice carrying the
human SMN2 gene (Smn
2/2 SMN2
þ/þ) (43). Consistent
with previous ﬁndings, total SMN2 transcript levels are
higher in CNS tissues such as cerebrum and spinal cord com-
pared with mesodermal and endodermal tissues such as skel-
etal muscle, heart and liver (19). Similarly, LT-SMN2
transcripts display considerably higher expression levels in
CNS tissues with a .3-fold higher expression in spinal
cord compared with muscle, heart and liver, suggesting that
the amounts of SMN protein derived from LT-SMN2 are suf-
ﬁcient to modulate motor neuron degradation (Supplementary
Material, Fig. S1). However, SMA disease severities appear
to be modiﬁed by multiple mechanisms. In rare cases, haploi-
dentical SMN1-deleted siblings show highly discordant SMA
phenotypes ranging from affected to unaffected (44). In these
families it has been shown that the SMA phenotype can be
inﬂuenced by elevated expression of an indepen-
dent modifying gene, Plastin 3, which protects against
SMA in females (45). Exemplary analysis of nt positions
2296 and 2290 in two of these families (#34, #482) (44)
revealed no differences in DNA methylation between
haploidentical affected and unaffected individuals (data not
shown).
Despite the apparent correlation between the CpG methyl-
ation levels at nt positions 2296 and 2290 and the disease
severity, the ﬁnding that LT-SMN2 expression is silenced by
DNA methylation is especially important regarding pharmaco-
logical SMA therapy using HDAC inhibitors. The funda-
mental mechanisms of epigenetic gene regulation, DNA
methylation and histone acetylation, have shown to be inter-
linked (26,27). Consistent with these ﬁndings we demonstrate
that a panel of ﬁve pan-HDAC inhibitors including the
hydoxamic acid vorinostat (SAHA) as well as the cyclic tetra-
peptide romidepsin (FK-228) are able to bypass LT-SMN2
gene silencing in SMA ﬁbroblasts (Fig. 5) and human
OHSCs (Fig. 6), resulting in up to 5-fold inductions of total
SMN2 transcript levels. In contrast, the HDAC isoenzyme
selective inhibitors MS-275, VPA and PB display only moder-
ate effects (Figs 5 and 6). These ﬁndings highlight functional
differences between HDAC inhibitors regarding pharmaco-
logical SMA therapy and suggest that pan-HDAC inhibitors
possess superior functional capacities to activate SMN2.
Given the fact that the pan-HDAC inhibitors vorinostat
(SAHA) and romidepsin (FK-228) are either FDA approved
or under clinical phase II evaluation for cancer treatment,
our data further highlight that these readily available com-
pounds might be considered as candidate drugs for SMA
therapy in case the ongoing clinical trials using VPA or PB
do not show the desired efﬁcacies. Especially vorinostat
appears to be promising due to the fact that this molecule
has shown to cross the blood-brain barrier and ongoing clinical
evaluation in cancer patients exempliﬁes a good oral bioavail-
ability and biological activity (46).
Moreover, we provide evidence of how LT-SMN2 gene
silencing by DNA methylation is regulated. ChIP experiments
using ML17 SMA ﬁbroblasts revealed that the
methyl-CpG-binding protein 2 (MeCP2) is localized at a
286 bp SMN2 promoter region (nt 2349 to 263) containing
all the three transcriptional SMN2 start sites at nt positions
2296, 2242 and 2163 as well as the differentially methyl-
ated CpG dinucleotides at positions 2296 and 2290
(Fig. 7G). MeCP2 binds to the SMN2 promoter region in
a methylation-dependent fashion (Fig. 7F) and MeCP2
knockdown induced LT-SMN2 mRNA expression (Fig. 7D).
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recruit HDACs to chromatin (26,47), suggesting that the regu-
latory component MeCP2 might be involved in mediating
SMN2 gene silencing by DNA methylation. Since the isoen-
zyme selective HDAC inhibitors MS-275 and VPA have
shown to inhibit HDAC1, HDAC2, HDAC3 (both MS-275
and VPA) and HDAC9 (MS-275) at doses used in our study
(32), the ﬁnding that these drugs do not counteract LT-SMN2
silencing suggests that the LT-SMN2 induction observed fol-
lowing pan-HDAC inhibitor treatment was due to inhibition
of the remaining classical HDACs (HDACs 4–8, 10, 11).
Thus, further analysis of the speciﬁc roles of MeCP2 and
HDAC isoenzymes in LT-SMN2 expression represent import-
ant steps to develop optimized HDAC inhibitors targeted to
overcome LT-SMN2 silencing.
Regarding the apparent correlation between
SMN2CGI 2
methylation levels and disease severity, continuative studies
are mandatory to assess whether the accurate quantiﬁcation
of DNA methylation levels at nt positions 2296 and 2290
represents a valuable tool to predict SMA disease progression
in the presence of identical SMN1 mutations and SMN2 copy
numbers. Furthermore, initial SMN1 promoter methylation
analyses of DNA samples derived from SMN2-deleted and
unaffected individuals revealed that SMN1 is subject to pro-
moter methylation very similar to SMN2 (Supplementary
Material, Fig. S2). Based on these ﬁndings one might specu-
late whether aberrant SMN1 promoter methylation may be
causative for SMA in patients showing at least one non-
mutated SMN1 gene copy.
MATERIALS AND METHODS
Chemicals
The following chromatin-remodelling compounds have been
used: M344 (382149, Calbiochem, San Diego, CA, USA),
MS-275 (382147, Calbiochem), PB (567616, Calbiochem),
zebularine (691400, Calbiochem), SAHA (270–288, Axxora,
Lo ¨rrach, Germany), VPA (P-4543, Sigma-Aldrich, St Louis,
MO, USA), scriptaid (S7817, Sigma-Aldrich), oxamﬂatin
(O3139, Sigma-Aldrich) and Aza (A-3656, Sigma-Aldrich).
Romidepsin (FK-228) was kindly provided by Gloucester
Pharmaceuticals (Cambridge, MA, USA). All test compounds
were dissolved in 100% DMSO or H2O (VPA).
SMA patient samples and DNA isolation
Informed consent was obtained from all SMA patients or their
parents. All patients fulﬁlled the diagnostic criteria for SMA
(48); SMA disease severities (type I SMA, MIM #253300;
type II SMA, MIM #253550; type IIIa/IIIb, MIM #253400)
were classiﬁed as described (49). Genomic DNA was isolated
from venous blood samples drawn for diagnostic purposes
using the salting-out method (50) and SMN1/SMN2 gene
copy numbers were determined as described previously (9).
The ﬁbroblast cell lines used in this study have been estab-
lished from skin biopsies and were cultured as described
(14). Fibroblasts were cultured for the indicated time spans
and harvested by trypsinization. DNA was isolated from ﬁbro-
blast cell cultures using the QIAamp DNA Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s protocol.
Human OHSCs
Human hippocampi were obtained from patients with chronic
intractable temporal lobe epilepsy who underwent surgical
treatment in the Epilepsy Surgery Program at the Department
of Neurosurgery (University of Erlangen). For scientiﬁc use of
tissue specimens, informed and written consent was obtained
from all patients and studies were approved by the local
Ethics Committee of the University of Erlangen. Surgical
specimens were prepared and processed according to the inter-
face technique (51). In brief, hippocampal brain samples were
cut into 350 mm thick horizontal slices on a vibratome (Leica
Microsystems, Wetzlar, Germany). Each brain slice was trans-
ferred into culture plate insert membranes (BD Biosciences,
San Jose, CA, USA) and thereafter into 6-well culture dishes
(BD Biosciences) containing 1.2 ml culture medium as
described in detail (52). A day after preparation, culture
medium was changed, human OHSCs were exposed to the
test compounds or solvent only for 48 h and snap-frozen in
liquid nitrogen.
Protein sample preparation and western blot analysis
Human OHSCs and ﬁbroblast cell culture cell pellets were
resuspended in RIPA buffer (150 mM NaCl, 1% NP40, 0.5%
DOC, 0.1% SDS, 50 mM Tris, pH 8.0) to obtain whole cell
protein extracts. Denatured protein (7.5 mg) of each sample
were resolved by SDS–PAGE on 4–12% Bis–Tris Gels (Invi-
trogen, Carlsbad, CA, USA) and transferred to nitrocellulose
membrane by overnight wet blotting. Immunostaining of the
membrane was performed according to standard protocols
using the following antibodies: mouse monoclonal
anti-ß-tubulin (T 4026, Sigma-Aldrich, dilution 1:20 000),
mouse monoclonal anti-SMN (610647, BD Biosciences,
dilution 1:1,000) and horseradish peroxidase conjugated goat
anti-mouse IgG (115-035-003, Dianova, dilution 1:10 000)
as secondary antibody. Detection of signals was carried out
using the Super Signal West Pico chemiluminescence
reagent (Pierce, Rockford, IL, USA). Densitometric analyses
were performed using the Quantity One 1-D Analysis Soft-
ware (Bio-Rad, Hercules, CA, USA).
RNA isolation and quantitative RT–PCR analysis
Isolation of total RNA was performed using the RNeasy Mini
Kit and QIAshredder columns according to the manufacture’s
protocol (Qiagen). RNA concentrations were determined
spectrophotometrically. For semiquantitative PCR analyses,
reverse transcription (RT) was performed using oligo dT
primers and 1 mg of total RNA by applying the SuperScript
First-Strand Synthesis System (Invitrogen). Two microlitres
of each RT reaction was used for each RT–PCR. cDNAs
were ampliﬁed using primers of ß-actin (ß-actin-fwd:
50-AAC GGC TCC GGC ATG TGC AA-30, ß-actin-rev:
50-CTC AAA CAT GAT CTG GGT CAT CTT-30), CDK-4
(CDK-4-fwd: 50-CTA TGG GAC AGT GTA CAA GG-30,
CDK-4-rev: 50-GAT ATG TCC TTA GGT CCT GG-30),
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2279-fwd: 50-ACT CCA GCC TGA GCG
ACA-30, LT-SMN2
2274-fwd: 50-AGC CTG AGC GAC AGG
GCGA-30, LT-SMN2
2128-rev: 50-TCT ACG AGT GGT TAT
CGC-30, LT-SMN2
þ90-rev: 50-ATC ATC GCT CTG GCC
TGT GCC-30). The following PCR conditions were used:
5 min initial denaturation (958C), followed by 25–37 cycles
(958C for 15 s, 688C for 30 s and 728C for 35 s and ﬁnal exten-
sion step (728C for 5 min). PCR products were separated on
2% agarose gels and visualized by ethidium bromide staining.
For real-time quantiﬁcation of target gene expression, one step
RT–PCR was preformed using the QuantiTect SYBR Green
RT–PCR Kit (Qiagen) on an Applied Biosystems 7500
Real-Time PCR System (Applied Biosystems, Darmstadt,
Germany). Each 20 ml RT–PCR mix contained 10 ng total
RNA (4 ng/ml), 2 ml of the primer dilution, 10 ml  2 Quanti-
Tect SYBR Green RT-Master Mix and 0.2 ml QuantiTect RT
Mix. One-step RT–PCR reactions were carried out in 96-well
optical reaction plates, covered with Optical Adhensive
Covers (Applied Biosystems). Cycling conditions were as
follows: 508C for 30 min (RT step), 958C for 15 min and 40
cycles of 948C for 15 s, 558C for 30 s and 728C for 35 s. Real-
time RT–PCR was conducted four times for each gene and
each RNA sample and results is given as mean+SEM. The
comparative method of relative quantiﬁcation (2
2DDCt) was
used to calculate the relative expression levels of each target
gene (normalized to ß-actin) compared with the non-treated
control samples. RT–PCR speciﬁcity of each reaction was
veriﬁed by melting curve analysis and conﬁrmed by 2%
agarose gel electrophoresis. Whenever possible, amplicons
have been designed to span exon borders to exclude false
positive detection of genomic contaminations. The following
primers have been used for quantitative real-time RT–PCR:
LT-SMN2-fwd 50-ACT CCA GCC TGA GCG ACA-30,
LT-SMN2-rev 50-TCT ACG AGT GGT TAT CGC-30.
SMN2: Quantitect primer assay QT01673679 (Qiagen),
ß-actin: Quantitect primer assay QT00095431 (Qiagen),
MeCP2: Quantitect primer assay QT00039361 (Qiagen). On
cDNA level, full-length SMN transcripts derived from SMN1
and SMN2 are identical except for two silent nt differences
in exons 7 and 8. SMN2 Quantitect primer assay
QT01673679 ampliﬁes exons 5 and 6. Please note that the
SMN2 primers used also detect SMN1 when present.
Bisulphite genomic sequencing
DNA methylation analysis was carried out by bisulphite
genomic sequencing using the pyrosequencing technology as
described in detail (53). Bisulphite conversion of DNA
(1 mg per sample) was performed using the EpiTect Bisulﬁte
Kit (Qiagen) according to the manufacturer’s protocol.
Regions of interest were ampliﬁed by nested PCR using
AmpliTaq Gold (Applied Biosystems) and biotinylated fwd/
rev primer for the inner PCRs. The PCR conditions were as
follows: 958C for 5 min, followed by 40–50 cycles (958C
for 15 s, 52–558C for 45 s, 728C for 1 min) and a ﬁnal exten-
sion step of 5 min at 728C. The biotinylated PCR products
(25 ml) were cleaned up using Streptavidin SepharoseTM
High Performance (GE Healthcare, Uppsala, Sweden) and a
PyroMark Vacuum Prep Workstation (Biotage, Uppsala,
Sweden). The puriﬁed PCR products were used for the pyro-
sequencing reaction according to the manufacturer’s protocol
using Pyro Gold Reagents and the PSQ96 MA System
(Biotage). Sequence analysis and quantiﬁcation of
CpG-dinucleotide methylation was performed using Pyro
Q-CpG software (Biotage). Cloning of PCR products was per-
formed using the TOPO TA Cloning Kit with One Shot
TOP10 chemically competent Escherichia coli and the
pcDNA3.1/V5-His Vector (Invitrogen). Plasmids of at least
nine positive clones were isolated using the QIAprep Spin
Miniprep Kit (Qiagen) according to the manufacturer’s proto-
col. Inserts were sequenced using the BigDye Terminator
Cycle Sequencing Kit V1.1 (Applied Biosystems) and the
T7 forward primer. The primers used for bisulphite genomic
sequencing (ampliﬁcation, cloning, sequencing) are given in
the Supplementary Material, Table S1. Please note that all
primers given in the Supplementary Material, Table S1
detect SMN1 and SMN2 due to identical promoter sequences.
siRNA-mediated knockdown of MeCP2
siRNA-mediated knockdown was performed as described pre-
viously (54). Brieﬂy, 1 day before transfection 1   10
5 SMA
ﬁbroblast cells were plated out in each well of a 6-well
culture dish. Cells were transfected with MeCP2 siRNA
(Qiagen, Hs_MeCP2_7, SI02664893, target sequence: ACG
GAG CGG ATT GCA AAG CAA) or AllStars negative
Control siRNA (Qiagen, 1027281) at a ﬁnal concentration of
50 nM using DharmaFECT 1 siRNA Transfection Reagent
(Dharmacon, Bonn, Germany). Transfection efﬁcacy was con-
trolled by transfection with siControl TOX transfection control
(Dharmacon, D-001500-01-20). Cells were harvested after
48 h. RNA isolation and real-time PCR analyses were per-
formed as described earlier.
Chromatin immunoprecipitation
ChIP experiments were carried out using the LowCell# ChIP
Kit (Diagenode, Lie `ge, Belgium) according to the manufac-
turer’s instructions. Brieﬂy, 3   10
5 ﬁbroblast cells were
used for each analysis. Cells were harvested by trypsinization.
Proteins were cross-linked to DNA by adding formaldehyde to
a ﬁnal concentration of 1% for 8 min at room temperature to
the trypsinized cells. The ﬁxation reaction was stopped by
adding glycine to a ﬁnal concentration of 0.125 M and sub-
sequent incubation for 10 min at room temperature. Chromatin
was sheared using a Bioruptor (Diagenode), utilizing
maximum power for 15 min with 30 s on/off cycles at 48C.
Five microgram of the MeCP2 antibody (Diagenode) per reac-
tion was bound to the Protein A-coated paramagnetic beads
which were included in the Kit. One hundered microlitre of
sheared chromatin were added to the antibody-coated para-
magnetic beads and incubated overnight at 48C with rotation.
Chromatin was immunoprecipitated and washed by using a
Magnetic Rack (Diagenode). Thereafter DNA was puriﬁed
from the antibody coated beads by using DNA purifying
slurry and incubation of the samples in boiling water for
10 min. This step was followed by addition of proteinase K
(Diagenode) and incubation at 558C for 30 min in a thermo-
mixer (1000 rpm). Subsequently the samples were incubated
again in boiling water for 10 min to elute the DNA. DNA
Human Molecular Genetics, 2009, Vol. 18, No. 2 315was analysed by real-time PCR on a 7500 Real-Time PCR
System (Applied Biosystems), using Power SYBR Green
PCR Master Mix (Applied Biosystems) and the primers
listed in the Supplementary Material, Table S1. All PCRs
were performed at least in triplicates.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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